Elizabeth Wagner is a life science executive who leverages over 18 years of relationship-building with CROs, labs, consultants and CDMOs to assist startups in progressing their product pipelines. As the former COO of Constant Therapeutics, she led the company to 3 Phase 2 assets (COVID, DMD-associated cardiomyopathy and stroke) and progressed a peptide oral formulation program through GMP production. Her previous experience includes Corporate Development at Cubist Pharmaceuticals, Portfolio Planning at Genentech and Clinical Research at Genzyme.